Eli Lilly LLY signed a definitive agreement to acquire Verve Therapeutics VERV for a total deal value of nearly $1.3 billion.

Called STC-004, the treatment is a a Nav1.8 inhibitor that is ready for Phase 2 testing. Lilly said STC-004 might represent a next-generation, non-opioid treatment for chronic pain. “The global ...

Camurus licensed its FluidCrystal drug delivery tech to Eli Lilly for global development of long-acting incretin therapies targeting metabolic diseases.

INDIANAPOLIS, May 27, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and SiteOne Therapeutics, Inc. ("SiteOne"), a private biotechnology company developing small molecule inhibitors of ...

Eli Lilly's acquisition of SiteOne Therapeutics and STC-004 brings a once-daily NaV1.8 candidate, with early promising results but limited clinical data so far. Given Vertex’s Journalx’s ...

SiteOne’s drug candidate, STC-004, is on track to begin Phase 2 testing. SiteOne develops drugs that target sodium channels, which are found primarily in the peripheral nervous system.

The all-cash deal, worth up to $1 billion, would give Lilly rights to a sodium channel-targeting therapy for chronic pain called STC-004 that recently generated positive results in a phase 1 trial ...

The acquisition includes STC-004, a Phase 2 ready Nav1.8 inhibitor being studied for the treatment of pain. Upon the completion of the deal, the company expects to continue the development of STC ...

The only publicly known candidate in SiteOne’s portfolio is an oral pain treatment asset dubbed STC-004. STC-004 works by blocking the Nav1.8 sodium channel, a voltage-gated channel primarily ...

The transaction includes STC-004, a Phase 2 ready Nav1.8 inhibitor being studied for the treatment of pain. STC-004 may represent a next-generation, non-opioid treatment for patients suffering ...